Insider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Insider Sells $12,015.52 in Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 13,654 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.88, for a total value of $12,015.52. Following the transaction, the insider now owns 26,346 shares of the company’s stock, valued at $23,184.48. This trade represents a 34.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Galectin Therapeutics Price Performance

Shares of GALT opened at $1.15 on Friday. The company has a market capitalization of $72.18 million, a P/E ratio of -1.58 and a beta of 0.69. Galectin Therapeutics Inc. has a one year low of $0.73 and a one year high of $4.27. The business’s 50 day simple moving average is $2.34 and its 200-day simple moving average is $2.43.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. HC Wainwright reissued a “neutral” rating on shares of Galectin Therapeutics in a report on Friday. StockNews.com raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th.

Institutional Trading of Galectin Therapeutics

Large investors have recently made changes to their positions in the business. Squarepoint Ops LLC raised its holdings in shares of Galectin Therapeutics by 75.4% in the second quarter. Squarepoint Ops LLC now owns 84,074 shares of the company’s stock valued at $190,000 after buying an additional 36,139 shares during the last quarter. Commonwealth Equity Services LLC raised its stake in shares of Galectin Therapeutics by 317.6% in the second quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock worth $1,092,000 after acquiring an additional 367,610 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Galectin Therapeutics in the second quarter worth about $146,000. Marshall Wace LLP acquired a new position in shares of Galectin Therapeutics during the second quarter worth approximately $43,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Galectin Therapeutics during the second quarter valued at approximately $227,000. Institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.